Slide 1: Transforming GI Detection and Screening
Transforming GI Detection and Screening
Slide 2: Cautionary Note Regarding Forward-Looking Statements
Cautionary Note Regarding Forward-Looking Statements This presentation contains “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995 that reflect our current expectations and views of future events. Significant kno
Slide 3: Our long-term, lifesaving vision
Our long-term, lifesaving vision is an ingestible capsule that, in a single, convenient, and noninvasive procedure, screens for multiple cancers— esophageal, gastric, pancreatic, liver, and colon—at early and still precancerous stages, using AI to analyze thousands of images captured in the GI tract
Slide 4: CapsoVision: Investment Highlights
CapsoVision: Investment Highlights Who We Are • Commercial-stage medical technology company • Capsule endoscopy solution providing superior imaging of GI tract • $3.6M revenue in Q2’26 from CapsoCam Plus • Robust intellectual property portfolio currently with 85 issued U.S. patents Superior Product
Slide 5: CapsoCam Plus for Small Bowel
CapsoCam Plus® for Small Bowel • FDA cleared and sold worldwide • Provides full circumferential view of the small bowel mucosa • Wire-free simplicity unburdens both providers and patients • Better visualization, longer battery life*, high exam completion rates and less data loss** • Proprietary AI t
Slide 6: Image Quality vs. Competitor
Image Quality vs. Competitor CapsoCam 360° FOV vs. PillCam 156° FOV CapsoCam Plus direct mucosal view, sees inner curve Competitor “tunnel” view, can miss inner curve © 2026 CapsoVision 6
Slide 7: CapsoCam Plus – For Small Bowel Capsule Endoscopy
CapsoCam Plus® – For Small Bowel Capsule Endoscopy CapsoCam Plus® Indication Visualize small bowel and detect pathology Target patient population Obscure GI bleeding, anemia, Crohn’s disease Status FDA cleared and sold worldwide through direct sales in the U.S. and direct/indirect worldwide Global A
Slide 8: How We Sell CapsoCam Plus
How We Sell CapsoCam Plus® rals • Direct Sales Force efer R Sales – 26 in U.S. Prospecting – 7 sales managers, trainers – 4 sales reps in Germany Closing Making the Sale Contact • Indirect ex-U.S. through distributors • Identify targets through prior CPT usage Sales Cycle • Initial focus on private
Slide 9: Detection and Screening for Colon Disease
Detection and Market Overview Screening for • Market growth is driven by rising colon cancer rates, increased awareness, and focus on early detection. Colon Disease • Detection and screening methods include FIT, Cologuard, endoscopy capsules, blood tests, and colonoscopy. • Currently, optical colono
Slide 10: Large Opportunity in Colon Disease Detection and Screening
Large Opportunity in Colon Disease Detection and Screening CapsoCam Colon Indication Non-invasive visualization of the entire colon for the detection of polyps Target Patient Population CRC diagnostic (initial patient population), surveillance and screening Status FDA 510(k) submission for CapsoCam
Slide 11: Efficient and Contemporary Workflow
Efficient and Contemporary Workflow Streamlined data Physician streams recovery and secure video and creates clinical processing diagnostic report anywhere Tele-supervised Cloud-based ingestion and storage, sharing convenient at home capability, and real retrieval time tracking © 2026 CapsoVision 11
Slide 12: AI-automated lesion detection
AI-automated lesion detection • Significantly reduces time spent by physician reading capsule videos • Increases procedure profitability • Enables a practice to scale to dozens of colon-capsule procedure per day • AI capability can deliver consistently high lesion detection rate • In-house AI core c
Slide 13: Improvements in CapsoCam Colon Gen 2
Improvements in CapsoCam Colon Gen 2 Added FOV • Significantly larger field of view (FOV) reduces chance of missing polyps and allows large polyps to be viewed more completely in a single frame • Improved image quality may improve assessment of subtle lesions • Reduced AI polyp detection false posit
Slide 14: CapsoCam Colon Gen 2 — Regulatory Progress
CapsoCam Colon Gen 2 — Regulatory Progress Next milestone ─ Following feedback ─ May 8, 2026 ─ 510(k) Planned FDA Pre-submission Meeting with FDA submission positive subject filed (Q261432) targeted for enrollment increased Q4 2026 Confidential © 2025 CapsoVision 14
Slide 15: Robust Development Pipeline Positioned for Long-Term Growth
Robust Development Pipeline Positioned for Long-Term Growth Pancreatic Cancer Detection Esophagus—Varix screening • No effective screening exists • Recommended for high-risk cirrhotic patients • A dilated papilla is correlated with pancreatic • 5M patients in the U.S. with cirrhosis*; neoplasia cons
Slide 16: Product Development Pipeline
Product Development Pipeline In Development Clinical Trial FDA Submission FDA Clearance Milestones CapsoCam Plus Continued commercial expansion Submitted FDA 510(k): CapsoCam Plus AI Module YE 2025; International launch (8/4/26) FDA510(k) submission: CapsoCam Colon (Gen 2) Q4 2026 Commenced clinical
Slide 17: Leadership: Commitment to Innovation and Results
Leadership: Commitment to Innovation and Results Johnny Wang David Garcia Doug Atkinson President & Chief Executive Officer Sr. Vice President of Finance Sr. Vice President of Sales © 2026 CapsoVision 17
Slide 18: Financial Overview
Financial Overview Revenue FY2025 Key Metrics $16M $14M • IPO in July 2025 (Nasdaq: CV) $12M • 15% year-over-year revenue growth $10M • 53% Gross Margin $8M $6M • No debt outstanding as of June 30, 2026 $4M $2M 0 FY2021* FY2022* FY2023 FY2024 FY2025 Small Bowel - U.S. Small Bowel - ex-U.S. * Unaudit
Slide 19: Growing commercial franchise today and a significantly larger market opportunity ahead
Growing commercial franchise today and a significantly larger market opportunity ahead PROVEN COLON PRODUCT DIFFERENTIATED AI LAUNCH CAPSULE: NEXT EXPANSION COMMERCIAL & DEFENSIBLE UNDERWAY MAJOR VALUE CREATES LONG- BUSINESS PLATFORM DRIVER TERM UPSIDE Confidential © 2026 CapsoVision 19
Slide 20: Transforming GI Detection and Screening
Transforming GI Detection and Screening